Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer
Your Article Summary
See Latest ArticlesSecond-line treatment for malignant pleural mesothelioma
Cancer Treatment Reviews, 11/05/09
Ceresoli GL et al. – Second–line therapy in MPM remains an ideal field in which to test new chemotherapy agents as well as new therapeutic strategies, including anti–angiogenic compounds, small molecules or monoclonal antibodies that target different molecular pathways.
Today in Lung/Thoracic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, phase III study
The Lancet, 10/26/09
Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer
Journal of Clinical Oncology, 10/29/09
New Advances in the Second-Line Treatment of Small Cell Lung Cancer
The Oncologist, 10/28/09
Sponsor
Article Search
Sponsor